Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent.
Introduction
Multiple myeloma (MM) is the most frequent cancer to involve the skeleton with up to 90% of patients with MM developing bone lesions. 2 This is in contrast to solid tumors that metastasize to bone, such as breast cancer and prostate cancer, where twothirds to three-quarters of these patients will develop bone metastasis during the course of their disease. Bone disease in MM is responsible for some of the most severe features of the disease with up to 60% of patients presenting with bone pain at diagnosis and 60% developing a pathologic fracture during the course of their disease. 3 The clinical and economic impact of MM bone disease in patients with MM can be catastrophic. Saad et al. 4 retrospectively assessed the impact of pathologic fractures on survival of patients with malignant disease. Patients with MM had the highest incidence of fracture (43%) compared to breast cancer, prostate cancer and lung cancer patients, respectively. MM patients who experienced pathologic fractures had at least a 20% increased risk of death compared to MM patients without pathologic fractures. Further, patients who had a prior skeletal related event, which included pathologic fracture, spinal cord compression syndrome and surgery to bone or radiation therapy to bone were more likely to develop new pathologic fractures compared with patients who did not have a prior skeletal-related event.
Pathogenesis of the increased osteoclast (OCL) activity in myeloma
Multiple myeloma patients lose bone much more rapidly than age-matched controls. Diamond et al. 5 reported that patients with MM who received glucocorticoid-containing treatment lost approximately 6% of their bone mineral density at the lumbar spine and almost 10% of their bone mineral density at the femoral neck over a 12-month period compared with agematched controls who were not on steroid therapy, and lost essentially no bone at the lumbar spine and approximately 1% of their bone mineral density at the femoral neck over the same time period. Further, the frequency of skeletal-related events is very high in patients with MM, with more than 30% of the patients having a fracture or requiring radiation therapy for bone pain on the placebo arm of a 21-month clinical trial. 6 These data clearly show that OCL activity is markedly increased in MM. Further, histologic studies of bone biopsies from patients with MM show that increased OCL activity occurs adjacent to MM cells. This has led to the hypothesis that local cytokines produced or induced by MM cells are responsible for the increased bone resorptive activity and OCL formation in MM. Growth factors released by the increased bone resorptive process also increase the growth of MM cells. 7 This creates a 'vicious cycle' in which the bone resorptive process releases growth factors that increase MM tumor burden that in turn results in increased bone destruction. In addition, adhesive interaction between MM cells and cells of the bone marrow microenvironment result in production of factors, which also increase angiogenesis and make the cells more chemotherapy resistant. 8, 9 Increased OCL activity appears to contribute both to the increased angiogenesis and tumor growth in MM. Several laboratories have shown that OCL themselves can support the growth of MM cells through cell-to-cell contact, which results in the production of interleukin (IL)-6 and osteopontin. 10, 11 In addition, Tanaka et al.
12 have shown that OCL enhance angiogenesis in MM through the production of factors, such as osteopontin, which together with vascular endothelial growth factor produced by MM cells, increase angiogenesis. OCL themselves may produce angiogenic factors, which further contribute to this process. 13 When MM cells home to the marrow, they adhere to bone marrow stromal cells through the binding of VCAM-1 (vascular cell adhesion molecule-1) on stromal cells and a 4 b 1 integrin on MM cells. These adhesive interactions increase the production of a multiplicity of factors in the bone microenvironment, which enhance OCL formation. The important factors that have been identified that are involved in the increased OCL formation in MM include RANK ligand (RANKL), osteoprotegerin (OPG), macrophage inflammatory protein (MIP)-1a, IL-6 and IL-3.
The RANK/RANKL signaling pathway is a critical component of the normal and malignant bone remodeling process. RANK is a transmembrane signaling receptor, which is a member of the SPOTLIGHT tumor necrosis receptor superfamily. It is found on the surface of OCL precursors. 14, 15 RANKL is expressed as a membrane-bound protein on marrow stromal cells and osteoblasts, and secreted by the activated lymphocytes. Its expression is induced by cytokines that stimulate bone resorption, 16 such as parathyroid hormone (PTH), 1,25-(OH) 2 D 3 and prostaglandins. 17, 18 RANKL binds to RANK receptor on OCL precursors and induces OCL formation. RANK signals through the nuclear factor-kB and JunN-terminal kinase pathways and induces increased osteoclastic bone resorption and enhanced OCL survival. 19 The important role of RANKL in normal osteoclastogenesis has been clearly shown in RANKL or RANK gene knockout mice. These animals lack OCLs, and as result develop severe osteopetrosis. [20] [21] [22] OPG is a soluble decoy receptor for RANKL and is a member of the tumor necrosis factor receptor superfamily. 23 It is produced by osteoblasts as well as other cell types and blocks the interactions of RANKL with RANK, thereby limiting osteoclastogenesis. In normal subjects, the RANKL/OPG ratio is very low. Studies using knockout mice for the OPG gene have shown the importance of OPG. OPG-deficient mice develop severe osteopenia and osteoporosis. 20, [23] [24] [25] [26] Pearse et al. 27 were the first to demonstrate that RANKL expression was upregulated in bone marrow biopsies of MM patients, whereas OPG expression was decreased. Terpos et al. showed that circulating levels of OPG and RANKL correlated with both clinical activity of MM, severity of bone disease and poor prognosis. 28 Furthermore, murine MM models also determined that the inhibition of RANKL can prevent bone destruction in either the SCID-hu model or the T2 MM syngeneic model of MM. 11, 28 These studies revealed that blocking RANKL, either with a soluble form of the RANK receptor or by OPG, minimizes bone destruction and tumor burden. In addition, MM cells have been reported to express RANKL, which may further contribute to the bone destructive process ( Figure 1 ).
MIP-1a is a chemokine that is produced by MM cells in 70% of MM patients, and is a potent inducer of human OCL formation. MIP-1a can increase OCL formation independently of RANKL and can potentiate both RANKL and IL-6-stimulated OCL formation. 29 Magrangeas et al. 30 reported that gene expression profiling showed that MIP-1a is the gene most highly correlated with bone destruction in MM. Further, Abe and collegues 31 have shown that elevated levels of MIP-1a also correlate with an extremely poor prognosis in MM. In vivo models of MM have shown that MIP-1a can induce OCL formation and bone destruction. Blocking MIP-1a expression in MM cells injected into SCID mice or treating the animals with a neutralizing antibody to MIP-1a results in decreased tumor burden and bone destruction. 32, 33 MIP-1a also plays an important role in homing of MM cells to the bone marrow. MIP-1a increases adhesive interactions between MM cells and marrow stromal cells by increasing the expression of b 1 integrins on MM cells. This results in increased production of RANKL, IL-6, vascular endothelial growth factor and tumor necrosis factor-a by marrow stromal cells, which further enhances MM cell growth, angiogenesis and bone destruction. Further, MasihKhan et al. 34 reported that the t4:14 translocation results in a constitutive expression of the fibroblast growth factor receptor 3, which results in high levels of MIP-1a. Patients with the t4:14 translocation have a very poor prognosis, which may reflect the increased MIP-1a production in this patient population. Terpos et al. 35 have shown that serum levels of MIP-1a correlate with the extent of bone disease and are predictors of survival for patients with MM. Patients with high MIP-1a levels had a significantly shorter survival.
IL-3, in addition to RANKL and MIP-1a, is also significantly elevated in bone marrow plasma of MM patients compared with normal controls. 36 IL-3 can induce OCL formation in human bone marrow cultures at levels similar to those measured in MM patient samples, and OCL formation induced by marrow plasma from MM patients could be inhibited by using a blocking antibody to IL-3. 36 IL-3 also indirectly influences osteoclastogenesis by enhancing the effects of RANKL and MIP-1a on the growth and development of OCLs. It also stimulates MM cell growth directly. 36 IL-3 also inhibits osteoblast formation through a factor produced by macrophages in the marrow microenvironment. 37 IL-6 has long been recognized as a proliferative factor for plasma cells, but is unclear if IL-6 levels correlate with disease status. 38 IL-6 is a potent inducer of human OCL formation. 39 Levels of IL-6 are elevated in MM patients with osteolytic bone disease when compared with MM patients without bone disease, as well as in patients with monoclonal gammopathy of unknown significance. 40 Most studies support the finding that IL-6 is produced by cells in the bone marrow microenvironment through direct contact with MM cells rather than MM cells themselves. These cells most likely are OCLs and stromal cells. Increased osteoblast production of IL-6 has been also reported in cocultures of human osteoblasts with MM cells. 41 Although the precise role of IL-6 in MM bone disease is yet to be determined, IL-6 production by OCLs can increase tumor burden leading to enhanced bone destruction as well as act as an autocrine/ paracrine factor to increase OCL formation. 10 Adhesive interactions between MM and stromal cells play a significant role both in homing of MM cells in the bone marrow and augmenting the bone destructive process. These adhesive interactions result in increased activation of nuclear factor-kB and p38 MAP-kinase. The latter is involved in the induction of RANKL expression by osteoblasts. Blocking p38MAP kinase results in a potent inhibition of IL-6 and vascular endothelial growth factor production as well as decreased adhesion of MM cells to marrow stromal cells. 42 Recently, Vanderkerken et al.
43
reported that the inhibition of p38 MAP kinase in the 5T2 MM murine model of MM decreased tumor cell burden prevented the development of bone disease and increased overall survival of mice having 5T2 cells. Therefore, this pathway may be a potential therapeutic target for novel therapies to ameliorate MM disease.
Osteoblast dysfunction in myeloma
In addition to the increased OCL activity, osteoblast activity is markedly suppressed in MM. Histomorphometric studies have shown that bone remodeling is uncoupled in MM with increased bone resorption and decreased or absent bone formation. Further, osteoblast apoptosis is markedly increased due to high cytokine levels and physical interaction between osteoblasts and MM cells. 44 Thus, MM patients have low levels of bone formation markers, such as alkaline phosphatase and osteocalcin. 45 This explains why bone scans underestimate the extent of MM bone disease, as bone scans reflect new bone formation (Figure 2 ).
In the last few years, signaling pathways involved in osteoblastic differentiation have been identified, which provide a better understanding of the inhibition of osteoblast activity in MM. In addition, these studies have identified several potential therapeutic targets for treating MM bone disease.
The formation and differentiation of osteoblasts from mesenchymal cells require the activity and function of the transcription factor Runx2/Cbfal. Runx2/Cbfal-deficient mice (Runx2) completely lack osteoblasts and bone formation. 46 Human osteoblast differentiation is associated with increased Runx2/Cbfal activity without a change in Runx2 protein levels, although Runx2/Cbfal overexpression can also impair bone formation. 47 These results indicate that a time-dependent expression of Runx2 drives osteoblast differentiation and plays a critical role in this process.
Inhibition of Runx2/Cbfal activity in MM bone disease has been shown. When MM cells were cocultured with osteoprogenitor cells, the MM cells inhibited osteoblast differentiation and reduced numbers of both early osteoblast precursors, as well as the more differentiated precursors. 48 This effect was mediated by blocking Runx2/Cbfal activity in osteoprogenitor cells. In addition, as Runx2/Cbfal stimulates the secretion of the RANKL decoy receptor, OPG, in osteoprogenitor cells, 49 it is possible that the inhibition of Runx2/Cbfal activity also increases osteoclastogenesis. The interaction between Runx2/Cbfal and MM cells is mediated by cell-to-cell interaction between MM cells and osteoprogenitors. This cell-to-cell interaction is dependent on a 4 b 1 on MM cells and VCAM-1 on osteoblast precursors, as neutralizing anti-a 4 b 1 antibodies reduce the inhibitory effect of MM cells on Runx2/Cbfal activity. 48 Interleukin-3 appears to play a dual role in the bone destructive process in MM. As noted above, it can stimulate OCL formation and bone resorption, and in addition, indirectly inhibit osteoblast formation. Treatment of primary mouse or human marrow stromal cells with IL-3 inhibited bone morphogenic protein-2 stimulated osteoblast formation, and marrow plasma from MM patients that expressed high IL-3 levels inhibited osteoblast differentiation, which was reversed by an anti-IL-3 antibody. 37 Interleukin-7 also can inhibit osteoblasts in MM. IL-7 levels are increased in marrow plasma samples from patients with MM compared with normal controls. 48 IL-7 is a very potent inhibitor of osteoblast differentiation and can affect osteoblast formation in several ways including interfering with Runx2 activity. 48, 50, 51 Wnt signaling pathway inhibitors in myeloma bone disease
The Wnt signaling pathway plays an important role in skeletogenesis by promoting the proliferation, expansion and survival of pre and immature osteoblastic cells. 52 Osteoblasts produce several soluble inhibitors of the canonical Wnt pathway, including Dickkopf (DKK1), secreted frizzled-related proteins and Wnt inhibitor factor.
Tian et al. 53 reported the production of DKK1 by primary CD138 þ MM cells, but not by plasma cells from monoclonal gammopathy of unknown significance patients and showed the correlation of the levels of DKK1 mRNA with focal bone lesions in patients with MM. Politou et al. 54 have confirmed the increased DKK1 levels in the sera of MM patients, and Kaiser et al. 55 have reported that serum DKK1 levels correlate with the extent of bone disease in MM patients. Interestingly, in contrast, patients with advanced disease as well as some human MM cell lines did not express DKK1, suggesting that these inhibitors may mediate bone destruction only in the early phases of disease. 53 Further, administration of an anti-DKK1 antibody to SCID-hu mice implanted with fetal bone, which was injected with 11 MM cells, inhibited MM cell growth and increased bone formation in implanted bone. 56 MM cells also produce secreted frizzledrelated protein-2, 57 which may suppress osteoblast differentiation in MM.
In addition to the inhibition of osteoblastogenesis, elevated DKK1 levels can also enhance osteoclastogenesis. Wnt signaling in osteoblasts increases the expression of OPG 58 and downregulates the expression of RANKL, 59 suggesting a possible mechanism by which the inhibition of Wnt signaling in osteoblasts would indirectly increase osteoclastogenesis. Taken together, these studies indicate that DKK1 is a key regulator of bone remodeling in both physiological and pathological conditions and blocking this factor may contribute to both stimulation of osteoclastogenesis and inhibition of osteoblasts in myelomatous bones. Thus, multiple stimulators of OCL activity and suppressors of osteoblast differentiation are present in MM and together result in the devastating bone disease present in these patients (Figure 3 ).
Novel therapies for the treatment of bone disease in myeloma
Bisphosphonate therapy is the mainstay for treating MM bone disease. 60, 61 However, bisphosphonate therapy only decreases skeletal-related events by 50% and is associated with a low incidence of renal toxicity and osteonecrosis of the jaw. Thus, new agents to treat MM bone disease are needed, and recently, the better understanding of the pathophysiology of MM bone disease has identified several new therapeutic targets for treating patients.
Denosumab
RANKL is responsible for OCL-mediated bone resorption in a broad range of pathological conditions and plays a key role in MM bone disease (see above). Denosumab is a fully human monoclonal antibody that binds RANKL with high affinity and specificity and inhibits RANKL-RANK interaction, mimicking the endogenous effects of OPG, a soluble RANKL decoy receptor. Phase 1 clinical trials in healthy postmenopausal women and in patients with MM or breast cancer showed that single and multiple subcutaneous injections of denosumab caused rapid and sustained suppression of the markers of osteoclastic bone resorption with a favorable safety profile. 62 A recent phase II trial of denosumab as a single agent in patients with plateau phase or progressive MM showed that denosumab significantly inhibited skeletal-related events but did not significantly decrease tumor burden. 63 Denosumab appears to have little toxicity, and multiple phase III trials of denosumab in patients with bone metastasis are ongoing.
Bortezomib as a potential bone anabolic agent in myeloma
Bortezomib is a highly active agent for treating MM. Bortezomib is a proteasome antagonist that induces MM cell apoptosis. Clinical trials with bortezomib indicated that it may also increase osteoblast activity, induce new bone formation and potentially repair lytic bone lesions. Degradation of proteins by the ubiquitin-proteasome pathway plays a critical role in MM cell survival, and clinical trials of proteasome inhibition with bortezomib have shown it to be an effective anti-MM agent. 64 The proteasome pathway is also an important regulator of osteoblast differentiation, 65 and proteasome inhibition can induce new bone formation in rodents.
Zangari et al. 66 conducted a retrospective analysis of three trials of bortezomib in patients with relapsed MM. In all three trials, patients who had a partial response to bortezomib therapy had a transient-increased alkaline phosphatase level compared with nonresponders. Additionally, patients who responded to bortezomib treatment were compared with those who responded to dexamethasone. The bortezomib-treated group had higher serum levels of alkaline phosphatase than the dexamethasone responders, suggesting that the increase in the osteoblast marker is not merely a result of reduced tumor burden. A prospective study by Heider et al. 67 analyzed relapsed MM patients enrolled in clinical trials using bortezomib (alone or with dexamethasone) compared with other agents. Patients treated with bortezomib had increased levels of bone-specific alkaline phosphatase and osteocalcin, both markers of increased osteoblast activity. The increase in bone-specific alkaline phosphatase and osteocalcin was observed in patients whose MM responded to bortezomib treatment as well as nonresponders, but was not seen in the other treatment groups regardless of response. 68 Giuliani et al. 69 investigated the in vitro and in vivo effects of bortezomib in patients with MM. In human osteoblast precursor cultures, bortezomib increased the markers of osteoblast differentiation and osteoblast-specific transcription factors, and enhanced bone nodule formation. Bone marrow samples of patients responding to bortezomib had a significantly increased number of osteoblastic cells compared with nonresponders. These studies suggest that bortezomib can stimulate osteoblasts in patients whose MM responded to bortezomib. Oyajobi et al. 70 have also reported that bortezomib can increase bone formation in murine models of MM. Although, the mechanism of action for bortezomib's effect on osteoblast stimulation in MM has not been fully determined, Terpos et al. 71 reported that bortezomib decreased DKK1 and RANKL serum levels in MM patients suggesting that bortezomib affects DKK1 production.
IMiDs as OCL inhibitors
Immunomodulatory drugs (IMiDs) are highly active agents in the treatment of MM. 72 Anderson et al. 73 reported that CC-4047 (Actimid), which is a derivative of thalidomide, has similar actions as lenalidomide, and also inhibited OCL development by affecting the lineage commitment of OCL precursors. CC-4047 downregulated the expression of PU.1, a critical transcription factor for the development of OCLs. The downregulation of PU.1 in hematopoietic progenitor cells resulted in a complete shift of lineage development toward granulocytes and away from OCL. This inhibited OCL formation with a concomitant accumulation of immature granulocytes. Similarly, Breitkreutz et al. 74 showed that lenalidomide inhibited OCL formation by targeting PU.1 and downregulating cathepsin K. These results suggest that like bortezomib, IMiDs may have both bone and anti-MM effects.
Conclusions
Multiple myeloma bone disease is a major clinical problem for patients, which has a significant impact on both their survival and well-being. Studies over the last several years have identified several factors, which provide novel targets for treating patients with MM. The identification of the RANKL/ OPG pathway in MM has led to clinical trials of a fully human monoclonal antibody, denosumab, for treating patients with MM. Further, antagonists to CCR1, which can block the effects of MIP-1a on MM bone disease and tumor growth should be entering clinical trial in the next several years. In addition, antibodies to DKK1 are also in clinical trial, and should be available for testing in patients with MM in the near future. Whether MM bone lesions will heal when patients are treated with anti-DKK1, or whether the bone microenvironment in MM bone lesions has been so adulterated that new bone formation cannot occur at sites of previous bone destruction remains to be seen. Preclinical studies using anti-DKK1 or PTH suggest that there is a potential for MM bone lesions to heal, although clinically, this has not been seen except in case reports of patients using bortezomib. 75 Regardless, the prolonged survival of patients with MM who receive novel therapies, such as thalidomide, lenolidomide and bortezomib, plus many new agents that are in clinical trial, further shows the importance of developing new therapies for treating and ameliorating MM bone disease in patients. Thus, studies to understand the pathogenesis of MM disease continue to be very important because of their capacity to help us understand what drives the bone destructive process in MM and for potential new therapies for patients.
